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Purpose: We sought to determine whether further distance from a radiation
center is associated with lower utilization of external beam radiation therapy
(XRT).
Methods: We retrospectively identified patients with a new diagnosis of lo-
calized prostate cancer (CaP) within the New Hampshire State Cancer Registry
from 2004 to 2011. Patients were categorized by age, D’Amico risk category,
year of treatment, marital status, season of diagnosis, urban/rural residence,
and driving time to the nearest radiation facility. Treatment decisions were
stratified into those requiring multiple trips (XRT) or a single trip (surgery or
brachytherapy). Multivariable regression analysis was performed.
Results: A total of 4,731 patients underwent treatment for newly diagnosed
CaP during the study period, including 1,575 multitrip (XRT) and 3,156 single-
trip treatments. Of these, 87.6% lived within a 30-minute drive to a radia-
tion facility. In multivariable analysis, time to the nearest radiation facility was
not associated with treatment decisions (P = .26). However, higher risk cate-
gory, older age, married status, and winter diagnosis were associated with XRT
(P < .05). More recent year of diagnosis and urban residence were associated
with single-trip therapy (primarily surgery) (P < .05). There was a significant
interaction between travel time and season of diagnosis (P = .03), as well as a
marginally significant interaction with urban/rural status (P = .07).
Conclusion: Overall, further travel time to a radiation facility was not as-
sociated with lower utilization of XRT. These data are encouraging regarding
access to care for CaP in New Hampshire.
Key words access to care, health disparities, prostate cancer, rural health,
social determinants of health.
Treatment decisions for prostate cancer (CaP) are com-
plex and incorporate diverse patient concerns. These in-
clude objective considerations such as disease risk, pa-
tient age and comorbidities, as well as subjective issues
such as concern for particular side effects or treatment
logistics. These subjective issues may significantly impact
treatment decisions, given the absence of a “gold stan-
dard” treatment for prostate cancer.1 As trade-offs in risk
and convenience are complex, “shared decision-making”
and multidisciplinary counseling are needed to ensure
patients are fully educated regarding surgery and radia-
tion therapy options and that their preferences are met.2
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An important nonmedical consideration for patients
contemplating treatment is the logistical ease or burden
of therapy. External beam radiation therapy (XRT) is
distinguished from other treatments by the need for
daily visits to a radiation treatment facility for up to 9
weeks, compared with the singular events of surgery or
brachytherapy. This presents a logistical challenge for
some patients. Indeed, with other malignancies there are
data suggesting that geographic distance to a radiation
center impacts the likelihood of pursuing XRT, reflecting
the difficulty of commuting. For example, Celaya et al
demonstrated that distance to a radiation center was as-
sociated with lower compliance with adjuvant radiation
therapy for breast cancer following breast-conserving
surgery (BCS) in New Hampshire, as well as a higher
probability of choosing mastectomy over BCS and radia-
tion in the first place.3 Other authors have demonstrated
the significant impact of distance on treatment decisions
for breast cancer.4-8 For prostate cancer, however, there
are limited prior studies evaluating the impact of travel
burden on treatment decisions. Cetnar et al reported that
travel distance was not associated with use of curative
versus noncurative therapies in the state of Wisconsin,
but there have been no studies evaluating associations
with actual travel time, or decisions regarding types
of therapy.8 Urban versus rural residence, reflecting
commuting time to larger hospitals, has been studied in
relation to treatment decisions, with mixed results.9,10
We have anecdotally observed that some patients are
deterred from pursuing XRT based on longer travel time
and the need for daily commuting. This concern may
be more relevant in a rural state such as New Hampshire
where patients may live more remotely. Currently, there
is a gap in knowledge whether travel time is a systematic
impediment to pursuing XRT; if such an impediment
exists, it would raise concerns regarding access to the
full range of treatment options. To answer this question,
we evaluated the association between travel time and
treatment decisions for newly diagnosed prostate cancer
in the New Hampshire State Cancer Registry.
Methods
After Institutional Review Board approval was obtained,
we performed a retrospective query of the New Hamp-
shire State Cancer Registry for patients with an incident
diagnosis of clinically localized prostate cancer from 2004
to 2011. Addresses of patients were geocoded by TeleAt-
las of Lebanon, New Hampshire, to an exact street address
(n = 4,063; 85.9%), or to the ZIP code geographic cen-
troid if only a post office box or rural route address was
provided (n = 665; 14.1%); geocode was missing for 3
cases.
Urban versus rural status was determined by the Rural
Urban Commuting Area (RUCA) classification of the pa-
tient’s geocoded address.11 RUCA codes are defined using
population density, urbanization and daily commuting.
The system has a total of 33 categories, which are com-
monly grouped together to form classifications of urban,
large rural, and small rural. We used RUCA categoriza-
tion C, which aggregates codes into urban and rural.
We obtained a list of facilities approved to provide ra-
diation therapy in New Hampshire and Vermont from
the New Hampshire Health Services Planning and Re-
view Board. Approved radiation treatment facilities in
Massachusetts and Maine were identified from their re-
spective state cancer registries. Radiation facilities in New
Hampshire and in surrounding states were geocoded in
ArcGIS v.10.1 (ArcGIS ESRI, Redlands, CA, USA) using
the 2012 Streetmap N.A. network dataset.12 Travel time
was then calculated from the patient’s geocoded address
to the closest radiation facility.
Patients were categorized by age, D’Amico risk cat-
egory, year of treatment, marital status, urban/rural
residence, and estimated travel time to the nearest
radiation facility. D’Amico risk category is a widely used
prostate cancer risk stratification tool that incorporates
prostate-specific antigen (PSA), Gleason score, and stage
of disease to predict 5-year recurrence risk. We deter-
mined that a 30+ minute commute would reasonably
constitute a “longer” travel time, thus we stratified pa-
tients into <30 minutes versus 30+ minutes categories.
Then, patients were stratified by treatment into “XRT”
or “non-XRT” (surgery or brachytherapy alone). Only
first treatment was considered, such that patients who
underwent surgery and then adjuvant or salvage XRT
were considered “non-XRT” patients. A multivariable
logistic regression model was created to determine the
relationship between travel time and choice of initial
treatment. Statistical analysis was performed using R
Core Team 201513 with add-on package “vis-reg.”14
Results
A total of 4,731 patients underwent XRT (1,575), surgery
(2,531) or brachytherapy (625) as initial treatment for lo-
calized prostate cancer during the study period. These in-
cluded 1,580 low-risk, 1,661 intermediate-risk, and 1,490
high-risk patients. Demographics and disease characteris-
tics by treatment are shown in Table 1.
The distribution of travel times to the nearest radia-
tion center was positively skewed (Figure 1). The median
travel time was 12 minutes (mean 15.6 minutes), and
87% of patients had travel times <30 minutes. Outlying
travel times of >140 minutes in 3 patients were excluded.
2 The Journal of Rural Health 00 (2016) 1–7 c© 2016 National Rural Health Association
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All Cases XRT Brachytherapy Surgery Total P
No. % No. % No. % No. % No. % chi2
Age <.001
<50 136 2.9 2 0.1 2 0.3 132 5.2 134 4.2
50-65 2,469 52.2 424 26.9 278 44.5 1,767 69.8 2,045 64.8
66-75 1,702 36.0 787 50.0 303 48.5 612 24.2 915 29.0
>75 424 9.0 362 23.0 42 6.7 20 0.8 62 2.0
Total 4,731 100.0 1,575 100.0 625 100.0 2,531 100.0 3,156 100.0
D’Amico risk <.001
Low 1,580 33.4 305 19.4 408 65.3 867 34.3 1,275 40.4
Intermediate 1,661 35.1 606 38.5 160 25.6 895 35.4 1,055 33.4
High 1,490 31.5 664 42.2 57 9.1 769 30.4 826 26.2
Total 4,731 100.0 1,575 100.0 625 100.0 2,531 100.0 3,156 100.0
Residence <.001
Rural 1,997 42.3 786 50.0 273 43.8 938 37.2 1,211 38.5
Urban 2,721 57.7 785 50.0 351 56.3 1,585 62.8 1,936 61.5





30 4,144 87.6 1,335 84.8 535 85.6 2,274 89.8 2,809 89.0
>30 587 12.4 240 15.2 90 14.4 257 10.2 347 11.0
Total 4,731 100.0 1,575 100.0 625 100.0 2,531 100.0 3,156 100.0
Diagnosis year .001
2004-2006 1,515 32 567 36 316 51 632 25 948 30
2007-2011 3,216 68 1,008 64 309 49 1,899 75 2,208 70
Total 4,731 100.0 1,575 100.0 625 100.0 2,531 100.0 3,156 100.0
Marital status .001
Not Married 870 18.4 336 21.3 125 20.0 409 16.2 534 16.9
Married/common law 3,732 78.9 1,192 75.7 485 77.6 2,055 81.2 2,540 80.5
Unknown 129 2.7 47 3.0 15 2.4 67 2.6 82 2.6
Total 4,731 100.0 1,575 100.0 625 100.0 2,531 100.0 3,156 100.0
Season at DX .006
Winter 1,135 24.0 421 26.7 132 21.1 582 23.0 714 22.6
Nonwinter 3,595 76.0 1,154 73.3 493 78.9 1,948 77.0 2,441 77.3
Unknown 1 0.0 0 0.0 0 0.0 1 0.0 1 0.0
Total 4,731 100.0 1,575 100.0 625 100.0 2,531 100.0 3,156 100.0














In multivariable analysis, travel time to a radiation fa-
cility was not associated with treatment decisions, either
when dichotomized (Table 2) or treated continuously.
Changing the threshold for longer versus shorter travel
time continued to be nonsignificant (ie, 15 minutes, 20
minutes). Older age (>65 years), higher D’Amico risk
category (intermediate/high), married status, and winter
season of diagnosis were associated with a higher likeli-
hood of XRT (P < .05). Urban residence and more recent
year of diagnosis were associated with higher likelihood
of non-XRT treatment, primarily surgery (P < .05). In-
teraction terms demonstrated that increasing travel time
was associated with lower likelihood of XRT during non-
winter (vs winter) months (P = .03) and for urban (vs
rural) patients (P = .07) (see Figures 2A and B).
Discussion
Decisions regarding treatment for prostate cancer in-
tegrate diverse concerns including disease risk, patient
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Table 2 A Multivariable Analysis of Factors Affecting Likelihood of Undergoing XRT for Localized Prostate Cancer
95% Confidence Interval
Variable P value OR Lower Upper
Age (centered at 65)a <.001 2.18 2.06 2.31
Diagnosis in years 2007-2011 .016 0.83 0.71 0.97
Intermediate risk <.001 1.94 1.61 2.33
High risk <.001 2.82 2.34 3.41
Not marriedb .007 0.74 0.59 0.92
Urban residence <.001 0.50 0.36 0.69
Travel time (centered at 30 minutes)c .26 0.98 0.94 1.02
Winter diagnosisd <.001 1.58 1.25 2.00
Urban residence × travel time .074 0.99 0.97 1.00
Winter diagnosis × travel time .028 1.01 1.00 1.03
aORs shown for 5-year increment.
bIncludes divorced, widowed, separated, or never married.
cORs shown for 5-minute increment.
dMonths of December, January, February.
health status, resource availability, and subjective pa-
tient factors.1 Shared decision-making (SDM) has be-
come an integral part of treatment discussions to guide
patients through this complex process.2,15-17 The ab-
sence of a “gold standard” treatment for prostate cancer,
with guidelines suggesting consideration of all treatment
options,18 has increased the role of logistical and non-
medical considerations in these discussions. While the
outcome of SDM discussions is often that 1 treatment is
preferred for an individual, this is not true a priori and a
detailed discussion is needed to assist patients with their
decisions.
New Hampshire is a largely rural state, with tertiary
care concentrated at several larger centers. Our institu-
tion hosts a multidisciplinary prostate cancer clinic where
patients throughout the region may be referred for SDM
discussions with a urologist and radiation oncologist. In
this clinic we have remarked that patients have cited
the challenge of a longer daily commute as a deterrent
to XRT. This raised concern that geography may be im-
peding equal access to all treatment options in our state.
Indeed, prior study of breast cancer treatment in New
Hampshire has shown that travel distance may influence
treatment decisions. Celaya et al reported that women
with early stage breast cancer were less likely to choose
breast conserving surgery (BCS) plus radiation, rather
than mastectomy, if they lived farther from a radiation
facility. Furthermore, those who did elect BCS were less
likely to use adjuvant radiation if they lived >20 miles
away.3 There have been similar related studies as well.4-8
Our literature search revealed only 1 prior study
evaluating the relationship between travel distance and
prostate cancer treatment decisions. Cetnar et al found
that calculated distance to nearest radiation facility was
not associated with decision for curative therapy or XRT
in Wisconsin.9 These authors used a different method
of calculating distance (the North American Association
of Central Cancer Registries’ “great circle distance cal-
culator”). Notably, they used distance (“as a crow flies”)
rather than calculated travel time based on the road net-
work that may not represent actual travel burden. There
have been other studies evaluating the relationship be-
tween urban/rural residence, which reflects commuting
time to large town/metropolitan centers, and treatment
decisions. These studies have yielded mixed results; pa-
tients in rural Georgia were more likely to pursue XRT
compared with urban counterparts, while this relation-
ship was absent in Wisconsin.9,10
In our analysis, we found that travel time to the nearest
radiation center was not associated with treatment deci-
sions for prostate cancer; those with longer travel time
were no less likely to pursue XRT. This provides reas-
surance regarding access to XRT in New Hampshire. We
used a 30-minute threshold to determine longer versus
shorter travel time based on a subjective impression that
this would constitute a more burdensome daily trip. In-
terestingly, 87% of travel times were 30 minutes or less,
which reflects that most patients do live relatively close
to radiation centers in this region; in fact, median travel
time was 12 minutes. Numerous community hospitals of-
fer XRT, which may facilitate access, whereas tertiary sur-
gical care such as robotic prostatectomy tends to be of-
fered at a smaller number of centers. One conclusion of
our study is actually that the large majority of patients
live relatively proximate to a radiation center. Nonethe-
less, 12.4% of patients did have travel times >30 minutes,
4 The Journal of Rural Health 00 (2016) 1–7 c© 2016 National Rural Health Association
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and in our large cohort this represents 587 patients, thus
we believe we were able to meaningfully compare treat-
ment decisions in relation to this variable.
We found that urban residence was associated with
greater use of single-trip therapy (primarily surgery),
rather than XRT. This mirrors findings in the report
by Steenland et al regarding treatment decisions in
Georgia.10 We hypothesize that urban residence, and its
associated proximity to larger hospitals, offers easy access
to more state-of-the-art surgical care (eg, robotic prosta-
tectomy) and leads to greater likelihood of pursuing this
treatment.
As winter in northern New England can be inclement,
we evaluated the impact of season of diagnosis on treat-
ment decisions. Winter diagnosis was associated with
greater usage of XRT, which was somewhat counterin-
tuitive given challenges of commuting during this season
for treatment. However, this is less unexpected when re-
flecting on the logistics of therapy and considerations of
the disease. Season of diagnosis is not necessarily season
of treatment, as many patients will undergo androgen de-
privation therapy (ADT) therapy for 2+ months, which
gives flexibility regarding when to initiate radiation. Fur-
thermore, many prostate cancers will have a slow course
and do not require immediate treatment; thus some pa-
tients will simply delay treatment until the weather im-
proves.
To assess more subtle associations between travel time
and treatment decisions, we created interaction terms
between travel time and season of diagnosis, as well as
urban/rural residence. Indeed, longer travel time was as-
sociated with decreased likelihood of XRT for patients
diagnosed in nonwinter (versus winter) months, and to
a lesser extent for urban (vs rural) patients. It is possi-
ble that frequent use of ADT in advance of XRT leads
to these counterintuitive findings, in which longer travel
time in winter months was associated with lower use of
XRT, as these patients would not typically initiate XRT
until the spring. Ultimately, these conclusions are spec-
ulative, however, and further study is needed to better
understand this potential phenomenon.
Other factors were associated with treatment decisions
as well. Older age and higher risk category, not surpris-
ingly, were associated with greater likelihood of XRT;
at least conventionally, older patients with higher-risk
cancer have been steered toward nonsurgical treatment.
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Interestingly, though, more recent year (post-2006) diag-
noses were associated with higher likelihood of single-trip
intervention, which largely represented surgery. This
reflects our recent findings, published separately, that
surgical intervention has become significantly more
common for all risk categories in recent years in
New Hampshire, likely because of changing treatment
paradigms (ie, more aggressive use of surgery for higher-
risk cancer) and the advent of robotic surgery to the
state.19 Finally, “married” status was associated with
XRT; speculatively, it may be that those who are married
have greater logistical support for daily treatments.
Further study of marital status and social relationships is
needed to understand how these might impact treatment
decisions on a systematic basis.
Limitations and Strengths
This study has several limitations. Although the analyses
used high quality data collected by a population-based,
state cancer registry, the variables include very little per-
sonal risk factor information; thus, there may be con-
founders affecting treatment decisions that are not con-
trolled for in our analysis. Due to limitations in the data,
we used the nearest radiation facility in our analyses,
and this was not necessarily the facility chosen by the
patient for treatment. Presumably, some men may have
chosen to have radiation (or surgery) at a more distant
facility, but in those cases it would seem that travel time
was not a major concern. We used a “reasonable” but
somewhat arbitrary cutoff for longer versus shorter travel
time of 30 minutes; we did not choose the median or
mean travel time because this was relatively low. Still,
given the large cohort size we believe we were still able
to make meaningful comparisons between those with
longer and shorter commuting times. Finally, some un-
usual situations are not captured in our data, such as pa-
tients who have temporary housing for the duration of
their treatment. We hypothesize that these situations are
sufficiently rare to not skew the data sufficiently.
Strengths of the study included use of calculated travel
time on a road network rather than travel distance to the
nearest radiation center. Another strength of our study
was inclusion of out-of-state radiation facilities to deter-
mine “closest facility,” as patients do seek care in adjoin-
ing states depending on proximity and preferences.
We believe that further study is warranted to better un-
derstand how geography and resource availability may
impact decisions regarding prostate cancer treatment.
While studies like this evaluate population-based fac-
tors, future study merging these factors with patient-level
data (eg, disease risk, use of shared decision-making) are
needed to clarify how to optimize treatment of this com-
plex condition. Similar study in states with greater geo-
graphic distances, such as in the Midwest, may corrobo-
rate or disprove our findings.
Conclusion
Travel time to a radiation center was not associated with
decisions regarding XRT versus alternative therapies for
treatment of localized prostate cancer in the state of New
Hampshire. This may result from relative proximity to a
treatment center for most of the population, and flexi-
bility in timing of XRT for many diagnoses. Overall these
findings are encouraging regarding access to all treatment
options for prostate cancer in New Hampshire.
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